v3.26.3
Supplemental Disclosures (Tables)
9 Months Ended
Sep. 30, 2026
Payables and Accruals [Abstract]  
Schedule of Other Current Assets

Other current assets consisted of the following (in thousands):

 

 

 

September 30, 2026

 

 

December 31, 2025

 

Settlement payment due from Sarepta

 

$

39,000

 

 

$

—

 

Net cost reimbursement due from AbbVie

 

 

7,493

 

 

 

10,871

 

Accrued interest on investments

 

 

961

 

 

 

1,004

 

Other

 

 

692

 

 

 

1,030

 

 

 

$

48,146

 

 

$

12,905

 

Schedules of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

September 30, 2026

 

 

December 31, 2025

 

Accrued personnel costs

 

$

16,037

 

 

$

17,418

 

Accrued external research and development expenses

 

 

8,412

 

 

 

10,229

 

Accrued external general and administrative expenses

 

 

1,880

 

 

 

1,301

 

Accrued royalties and sublicense fees

 

 

1,150

 

 

 

8,652

 

Accrued purchases of property and equipment

 

 

242

 

 

 

33

 

Other

 

 

1,890

 

 

 

757

 

 

 

$

29,611

 

 

$

38,390